Sensitization of TRAIL-resistant cells by inhibition of heat shock protein 90 with low-dose geldanamycin

Keyphrases

• Adverse Effects 20%
• Apoptosis 50%
• Cancer Cells 10%
• Cancer Therapy 20%
• Caspase Activity 10%
• Clinical Trials 10%
• Complex Proteins 10%
• Geldanamycin 100%
• Heat Shock Protein 90 (Hsp90) 100%
• High Dose 10%
• IKK Complex 10%
• Induced Apoptosis 10%
• Lethal Dose 10%
• Ligand Effects 10%
• LNCaP 10%
• LNCaP Cells 10%
• Nuclear factor-B 30%
• Nuclear Transport 10%
• Prostate Cancer Cells 10%
• Resistant Cells 100%
• Resistant Prostate Cancer 10%
• Suboptimal Dose 10%
• Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) 100%
• Working Plan 10%

Biochemistry, Genetics and Molecular Biology

• Cancer Cell 20%
• Caspase 10%
• Clinical Trial 10%
• Complement Factor B 30%
• Drug Megadose 10%
• Geldanamycin 100%
• Heat Shock Protein 100%
• Kinase 10%
• LNCaP 20%
• Low Drug Dose 100%
• Nuclear Transport 10%
• Phosphotransferase 10%
• Protein Complexes 10%
• Sensitization 100%
• Tumor Necrosis Factor 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 20%
• Alternative Complement Pathway C3 C5 Convertase 30%
• Caspase 10%
• Clinical Trial 10%
• Geldanamycin 100%
• Heat Shock Protein 90 100%
• Malignant Neoplasm 30%
• Nuclear Factor 30%
• Phosphotransferase 10%
• Prostate Cancer 10%
• Tumor Necrosis Factor Related Apoptosis Inducing Ligand 100%